NCT00563849已完成4 期
An Open-Label, Multi-Center Study to Evaluation of Leflunomide Plus Methotexate for the Treatment of Rheumatoid Arthritis in DMARDs:(Disease-Modifying Antirheumatic Drug) na¿ve or Restart (Skip DMARDs More Than 4 Weeks) Subjects.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 74
- 试验地点
- 2
- 主要终点
- The primary end point was a 20% improvement in the American College of Rheumatology criteria (ACR 20) at 20 weeks
研究概览
简要总结
To determine the efficacy and safety of the combination of leflunomide and methotrexate for treating active rheumatoid arthritis (RA) in an open noncomparative multicenter trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female between ages of 18 and 75 years old.
- •Female subjects must be of nonchildbearing potential (i.e., surgically sterile or at least 2 years postmenopausal) OR their participation is contingent upon the following:
- •They are practicing a medically accepted contraceptive regimen (acceptable methods must include one of the following: systemic contraceptive, oral or implanted estrogen/progestin; diaphragm with intravaginal spermicide; cervical cap; intrauterine device; or condom with intravaginal spermicide) AND
- •they are demonstrated not to be pregnant (by serum pregnancy test) or breast-feeding at the time of study entry AND
- •they intend to continue the contraceptive regimen and remain not pregnant throughout the study AND
- •they are willing to undergo pregnancy testing (serum) at screening and (urine) monthly thereafter AND
- •they are fully informed as to the risks of entering the trial and provide written consent to enter the trial; female patients not sexually active should also be adequately informed about appropriate methods of contraception AND
- •they agree to not get pregnant for 24 months after discontinuation of treatment with study medication or they undergo a washout procedure with cholestyramine or charcoal.
- •Male subjects must consent to practice contraception during the study. The subject needs to have clinically diagnosed rheumatoid arthritis including diagnosis of RA by ACR criteria greater than or = to 6 months prior to enrollment active disease by ACR criteria . Men wishing to father a child should consider discontinuing use of study drug and taking cholestyramine 8 gm 3 times daily for 11 days. In addition, males should consider discontinuation of methotrexate treatment and waiting an additional three months.
- •Active disease by ACR criteria despite methotrexate therapy for three of the following four criteria:
- •greater than or = to 9 tender joints
- •greater than or = to 6 swollen joints
- •greater than or = to 45 minutes of morning stiffness
- •ESR greater than or = to 28mm/hr
- •Subject must remain on unchanged doses of NSAIDs for at least 4 weeks prior to study drug administration and throughout the timecourse of the study.
- •Concomitant therapy will be permitted with corticosteroids at a dose of less than or = to 10 mg prednisone daily (or the steroid equivalent administered orally), provided the dose has been stable for at least 4 weeks prior to the study drug administration; dose must remain constant throughout the timecourse of the study.
- •Subjects must not receive intramuscular, intra-articular or intravenous corticosteroids within 4 weeks prior to initiating study participation or during the study.
- •Subjects must be able and willing to comply with the terms of this protocol. Informed consent must be obtained for all subjects before enrollment in the study.
排除标准
- 未提供
结局指标
主要结局
The primary end point was a 20% improvement in the American College of Rheumatology criteria (ACR 20) at 20 weeks
时间窗: 20 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient SettingPneumoniaNCT00034736Johnson & Johnson Pharmaceutical Research & Development, L.L.C.691
已完成
3 期
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)Arthritis, PsoriaticNCT00367237Merck Sharp & Dohme LLC115
已完成
4 期
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)Rheumatoid ArthritisNCT01185288AbbVie (prior sponsor, Abbott)309
Unknown
4 期
Optimal MTX Dose With Folic Acid Randomized Case-control TrialRheumatoid ArthritisNCT04066803Sun Yat-sen University160
招募中
4 期
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal CancerMetastatic Colorectal CancerNCT06118762The First Affiliated Hospital of Nanchang University30